Gordon Fung, MD
Cardiovascular Disease · San Francisco, CANPI 1215994827
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,750 of the $2,820 with a category attached, or 97.5%. Amgen accounts for 97.5% of it on its own, with 2 other manufacturers making up the rest. 2021 is the largest year on record at $2,750, more than ten times the $38 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 5 payments — averaging $563.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Regeneron$52
- E.r. Squibb & Sons, L.L.C.$18
Across 136 payments — averaging $1038.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$73K
- Boehringer Ingelheim Pharma GmbH & Co.kg$35K
- Novartis$33K
What the payments were for
- Consulting fees$2,75098%
- Food & beverage$702%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $2,750 |
| Regeneron | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
How this compares
$2,820 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $55,272 |
| EntrestoSacubitril/Valsartan | 25 | $26,451 |
| Praluent PenAlirocumab | 14 | $7,719 |
| Ezetimibe | 31 | $990 |
| Atorvastatin Calcium | 50 | $599 |
| Metoprolol Succinate | 35 | $534 |
| Carvedilol | 37 | $483 |
| ClopidogrelClopidogrel Bisulfate | 24 | $441 |
| Rosuvastatin Calcium | 25 | $355 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $323 |
| Simvastatin | 12 | $228 |
| Amlodipine Besylate | 28 | $185 |
| Losartan Potassium | 12 | $176 |
| Chlorthalidone | 14 | $167 |
| Spironolactone | 14 | $87 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in San Francisco
- Philip SagerSan Francisco$675K
- Javid MoslehiSan Francisco$307K
- Tony ChouSan Francisco$301K
- Lloyd KleinSan Francisco$149K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.